Monoclonal Antibody Core


The Monoclonal Core was established in 2000 and has been directed by Dr. Daniel Cawley since 2004.  The VGTI Monoclonal Core offers two basic services:  the generation of new monoclonal antibodies and the scaleup production and purification of antibody from existing cell lines (a stand -alone phase IV).  A project is typically done in four stages.

Stage One            Immunization

4 mice are given 2-3 injections with protein antigen.  Antisera titers are determined to identify animals for fusion and to set up an ELISA screening assay.

Stage Two            Fusion and hybridoma screening

Spleen cells from 2 mice are fused with mouse myeloma cells to generate hybridomas.   After ELISA screening, cell supernates are delivered to the client for testing.

Stage Three         Cloning and characterization of hybridomas

Parent hybridomas are limit dilution cloned, providing for stable growth and antibody production and monoclonality.  Several vials of frozen cells are made available to the client.

Stage Four            Antibody scaleup production and purification

In vitro scaleup in bioreactors provides antibody in the 50 mg range.  Antibodies are purified to greater than 90% using two chromatography steps.   A list of existing cell lines for Ab production is available upon request.


PHASE PROGRAM OHSU cost External Rate
ONE Immunization 800 1000


Fusion and screening



THREE Cloning 200 (per clone) 300 (per clone)
FOUR Antibody production/purification 1500 (per Ab) 1800 (per Ab)


Dr. Daniel Cawley
Oregon Health Sciences University
Vaccine and Gene Therapy Institute
505 NW 185th Ave
Beaverton, OR 97006

Cell: 971-235-7759
Office: 503-418-2707
FAX: 503-418-2719


OHSU Home | About OHSU | Search | Site Map | Contact OHSU
Health Care Services | Research Programs | Academic & Students | Regional Outreach

OHSU is an equal opportunity, affirmative action institution.
© 2001-2013, Oregon Health & Science University
OHSU Notice of Privacy Practices